Edit
Abscint: Molecular imaging in Oncology, Immunology and Cardiology
https://abscint.com/Last activity: 10.08.2026
Active
Company in Clinical Stage that develops platform production processes allowing fast production of cold kits for new applications/sdAbs.
Location: Belgium, Brussels-Capital, Ganshoren
Total raised: $3.18M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2023 | - | $3.18M | Qbic Fund |
Mentions in press and media 4
| Date | Title | Description |
| 10.08.2026 | Curium acquires Abscint SA | Original article on Curium website: Curium acquirs Abscint SA, expanding PET radiodiagnostic pipeline in oncology - Curium Pharma Boston, MA and Liege, Belgium – 10 August, 2026 – Curium™ a leading global radiopharmaceutical company, announ... |
| 02.06.2026 | ABSCINT announced compelling clinical results for HER2-targeted imaging | Brussels, Liège– May 28, 2026 – ABSCINT, a clinical-stage molecular imaging company, today announced compelling clinical results for its novel HER2-targeted imaging agent, 68Ga-ABS011 PET/CT. Designed to enable whole-body, non-invasive asse... |
| 26.09.2023 | ABSCINT raises € 3 million round to initiate Phase II Clinical Trials | Brussels, Liège, September 25, 2023 - ABSCINT has secured EUR 3 million for its technology platform that enables rapid targeting and visualisation of specific molecular markers throughout the entire body via a PET scan. ABSCINT is actively ... |
| 05.12.2022 | ABSCINT raises new financing round | Brussels, Liège, December 5, 2022. ABSCINT is a clinical stage molecular imaging company that develops radiopharmaceutical diagnostics to guide patients and doctors to the right treatment at the right time. Its technology platform relies on... |